ABSTRACT
INTRODUCTION
Methotrexate, is probably the oldest in the list of drugs used in the second line treatment of Arthritis. The beneficial and the side effects of the drug had been a topic of study in the yesteryears and its dosage-related toxicity is established beyond doubts now. The drug has also been used with enough success in patients of rheumatoid and psoriatic arthritis. Methotrexate (MTX) has been used widely as a Disease modifying anti-rheumatoid drug (DMARD) with varying percentage of success (1). Combinations of DMARD's are used by rheumatologists all over the globe. The most commonly used combinations are MethotrexateHydroxychloroquine (MTX-HCQ), Methotrexate-Sulfsalazine (MTX-SSZ) and Sulfsalazine-Hydroxychloroquine (SSZ-HCQ). The most commonly used combination of MethotrexateHydroxychloroquine (MTX-HCQ) are prescribed by 99 % of rheumatologists in the United States (2). The role of cytokines in inflammation has been dealt with in detail and a conclusive hypothesis on their mode of action has been arrived at (3).
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is a cytokine involved in promotion of proliferation among haemopoeitic progenitors (4) . The molecule has been used with varying degree of success as an adjuvant in the therapy of cancer to enhance the Absolute Neutrophil Count (ANC). (5) The molecule is known to mediate its effects through a distinct receptor known as the GM-CSF receptor (GM-CSF R) which occurs on monocytes neutrophils, eosinophils (6) . The receptor, first isolated in 1989 was shown to be a 85 kDa molecule and a member of the family of receptors which includes IL-2, IL-4, IL-6, IL-7, erythropoeitin, growth hormone and prolactin (7) . The high affinity receptor is composed of two subunits alpha and beta subunits. The alpha subunit is critical for high affinity binding and initiating ligand-receptor interactions (8) .
The role of the GM-CSF receptor (CD 116) has not yet been fully understood. The present study was taken up to study the expression of the receptors on neutrophils isolated from synovial fluids of patients on combination therapy for arthritis.
MATERIALS AND METHODS
All cases chosen for the study were known cases of arthritis. Subjects selected for the study were women aged between 40-45 years who were confirmed cases of seropositive Rheumatoid Arthritis.
Group I consisted of 15 individuals on MTX-HCQ therapy since the diagnosis of RA. They were on Methotrexate at 7.5 mg in three doses per week (i.e. 2.5 mg in three divided doses 12 hours apart for a week) and Hydroxychloroquine 500 mg daily.
The Group II consisted of 15 individuals who were also confirmed cases of seropositive rheumatoid arthritis and advised SSZ-HCQ combination (devoid of MTX) as their treatment regimen (Group II). They received 500 mg Hydroxychloroquine and 1 g Sulfsalazine daily.
Age & sex matched Normal controls were cases who presented for orthopedic surgery but not known cases of RA were also included in the study. (Group III).
Synovial fluid was drawn from subjects of all study groups during surgical correction of joint deformities in RA or surgery for any other cause excepting RA. The neutrophils were isolated from the synovial fluid by centrifugation (1500 rpm) at 4 0 C on a REMI C 24 centrifuge for 20 minutes and stored frozen in Cell Resuspension Buffer (CRB) (9) . Cell resuspension buffer (CRB) was a modified Dulbecco's Phosphate buffered saline (DPBS) containing 5 mM KCl, 147 mM NaCl, 1.9 mM KH 2 PO 4 , 1.5 mM CaCl 2 , 1.1 mM MgCl 2 , 0.1 % glucose and 0.1 % bovine serum albumin (pH 7.4).
The cell suspension was then thawed and cell count determined by method of turbidimetry and fixed at 10 2 cells per ml. The standardized cell suspensions were then subjected to membrane solubilization of the receptor. The cell pellet obtained therefore was suspended in DPBS. The resuspended pellet was subjected to osmotic lysis. The resulting lysate was subjected to centrifugation at 45,000 rpm and 4 0 C. The pellets obtained were carefully transferred into a fresh sterile polypropylene tube, resuspended in Membrane resuspension Buffer (MRB) and stored frozen until further use. Membrane resuspension buffer (MRB) consisted of 100mM KCl, 10 mM NaCl, 10mM Hepes, 1mM EDTA, 0.1 mM Dithiothreitol, 1mM PMSF (pH 7.3).
After thawing on ice, the membrane pellets were treated with 1 ml of 5 M NaCl per 4 ml of MRB. The mixture was vigorously shaken and subjected to centrifugation at 1,00,000 g for 35 minutes. The supernatant was discarded and the pellet resuspended in MRB. Solubilisation was rendered complete by adjusting the protein concentration to 1-2 mg/ml with MRB and addition of Triton-X-100 to make a final detergent concentration of 2 % (w/v). The solution was vortexed, kept on ice for 30 minutes and centrifuged at 1,00,000 g for 30 minutes at 4 0 C. The supernatant was then used for enzyme immunoassay (EIA) for quantification of GM-CSF R. The EIA was developed by us at our laboratory for the purpose using Monoclonal antibody against GM-CSF R (Serotec, UK). The microwell plates were procured from NUNC-Nalgene International. The developed EIA was standardized against a commercial kit procured from Immunotec, France. Specificity of the developed Enzyme immunoassay was determined to be 96.3 % and sensitivity was fixed at 92 %. Figure 1 . Statistical analysis was performed using the Mann -Whitney "U" test. Our results indicate a positive influence of MTX-HCQ combination therapy on GM-CSF receptor expression on neutrophils isolated from the synovial fluids of RA patients in comparison with SSZ-HCQ treated group (p < 0.01) and Normal controls (p < 0.01).
RESULTS

Results of the estimations are shown in
DISCUSSION
One of the biggest challenges that most rheumatologists face when treating patients with Rheumatoid arthritis is selecting the best DMARD, or combination of DMARD's. (2,10). However, many cannot arrive at a single best combination at once and frequent trials with several DMARD combinations have to be carried out before arriving at the best choice. Combinations of DMARD's are used by rheumatologists all over the globe. The most commonly used combinations of MTX-HCQ, MTX-SSZ and SSZ-HCQ are prescribed by 99%, 84% and 63% rheumatologists of United States respectively (2).
The increased uses of combinations were proposed owing to the fact that combinations could be safely used and with greater efficacy than mono-DMARD therapy. ( 11, 12, 13) . The most commonly used combination of MethotrexateHydroxychloroquine (MTX-HCQ) is known to have the lowest discontinuation rate (14) .
The destruction of joint tissue in RA is a result of a loss of the normal balances of the patient's inflammatory systems. The inflammatory response is under the control of a large family of cytokines, which act as "molecular messengers" during inflammatory reaction in RA. (15) The GM-CSF receptor has been implicated as a mediator of inflammation in RA. (16) . An increase in the expression of the receptor has been reported on monocytes (17) Gene amplification has been shown with respect to methotrexate and DHFR gene. (18) It needs to be elucidated whether a similar effect is the mechanism behind the current finding. Studies with affinity-purified receptor are being conducted for further ascertaining of the results. The sample size in the present study could not be increased owing to the rarity of RA patients consulting orthopedic surgeons for surgical correction of joint deformities. However, animal model studies with mono-DMARD administration could provide a greater basis for the explanation of our present finding thus allowing a closer approach to its molecular and physiological basis.
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